The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Harbour BioMed brings advanced antibody discovery platforms to the table
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Positions Curium as leading manufacturer of Lu-177 isotope
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Subscribe To Our Newsletter & Stay Updated
